Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -70.19% is 17% below its 5-year average of -60.13%, near the high end of its 5-year range (-624.94%–-23.24%).
As of the fiscal period ended Tuesday, June 30, 2026. 48.65% below its 12-month average of -47.22%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -70.19%.
RETURN ON EQUITY (ROE)
-70.19%
RETURN ON EQUITY (ROE) AVG TTM
-47.22%
RETURN ON EQUITY (ROE) AVG 3Y
-139.83%
RETURN ON EQUITY (ROE) AVG 5Y
-60.13%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-48.65%
CURRENT VS 3Y AVG
+49.80%
CURRENT VS 5Y AVG
-16.74%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.66%
median of 590 covered companies
CURRENT VS SECTOR MEDIAN
-77.00%
vs the sector median at left
Candel Therapeutics, Inc.
Market Cap
$753.22M
Return on Equity (ROE)
-70.19%
TTM Avg
-47.22%
3Y Avg
-139.83%
5Y Avg
-60.13%
Market Cap
$740.17M
Return on Equity (ROE)
N/A
TTM Avg
-222.26%
3Y Avg
276.12%
5Y Avg
157.82%
Market Cap
$770.55M
Return on Equity (ROE)
2.54%
TTM Avg
1.18%
3Y Avg
-43.07%
5Y Avg
-28.50%
Market Cap
$770.72M
Return on Equity (ROE)
-35.07%
TTM Avg
-26.66%
3Y Avg
-24.19%
5Y Avg
-5.48%
Market Cap
$780.99M
Return on Equity (ROE)
-40.21%
TTM Avg
-52.14%
3Y Avg
-52.14%
5Y Avg
-52.14%
Market Cap
$725.41M
Return on Equity (ROE)
-22.36%
TTM Avg
-60.32%
3Y Avg
-42.71%
5Y Avg
-132.49%
Market Cap
$723.84M
Return on Equity (ROE)
-25.03%
TTM Avg
-10.49%
3Y Avg
-5.87%
5Y Avg
-23.97%
Market Cap
$720.96M
Return on Equity (ROE)
15.36%
TTM Avg
25.54%
3Y Avg
15.72%
5Y Avg
18.75%
Market Cap
$787.12M
Return on Equity (ROE)
-35.02%
TTM Avg
-92.06%
3Y Avg
-115.35%
5Y Avg
-96.02%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $753.22M | -70.19% | -47.22% | -139.83% | -60.13% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $740.17M | N/A | -222.26% | 276.12% | 157.82% |
| Mesa Laboratories, Inc. (MLAB)vs › | $770.55M | 2.54% | 1.18% | -43.07% | -28.50% |
| Design Therapeutics, Inc. (DSGN)vs › | $770.72M | -35.07% | -26.66% | -24.19% | -5.48% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $780.99M | -40.21% | -52.14% | -52.14% | -52.14% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $725.41M | -22.36% | -60.32% | -42.71% | -132.49% |
| Cytek Biosciences, Inc. (CTKB)vs › | $723.84M | -25.03% | -10.49% | -5.87% | -23.97% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $720.96M | 15.36% | 25.54% | 15.72% | 18.75% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $787.12M | -35.02% | -92.06% | -115.35% | -96.02% |
| Geron Corporation (GERN)vs › | $795.49M | -31.97% | -50.13% | -87.97% | -79.93% |
ROE
-70.2%
ROA
-42.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -70.19% |
| 2026-03-31 | -39.43% |
| 2025-12-31 | -73.54% |
| 2025-09-30 | -28.40% |
| 2025-06-30 | -24.54% |
| 2025-03-31 | -53.00% |
| 2024-12-31 | -83.19% |
| 2024-03-31 | -624.94% |
| 2023-12-31 | -297.68% |
| 2023-09-30 | -138.68% |
| 2023-06-30 | -104.58% |
| 2023-03-31 | -67.37% |
| 2022-12-31 | -39.39% |
| 2022-09-30 | -23.24% |
| 2022-06-30 | -32.61% |
| 2022-03-31 | -51.00% |
| 2021-12-31 | -56.32% |
| 2021-09-30 | -76.52% |
| 2021-06-30 | -587.77% |
| 2021-03-31 | -94.54% |
